Li Yumei, An Lanfen, Jia Zhe, Li Jingxia, Zhou E, Wu Feng, Yin Zhengrong, Geng Wei, Liao Tingting, Xiao Wenjing, Deng Jingjing, Chen Wenjuan, Li Minglei, Jin Yang
NHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Cancers (Basel). 2022 Jul 18;14(14):3478. doi: 10.3390/cancers14143478.
Lung adenocarcinoma (LUAD) is a common pathological type of lung cancer worldwide, and new biomarkers are urgently required to guide more effective individualized therapy for patients. Ubiquitin-related genes (UbRGs) partially participate in the initiation and progression of lung cancer. In this study, we used ubiquitin-related gene pairs (UbRGPs) in tumor tissues to access the function of UbRGs in overall survival, immunocyte infiltration, and tumor mutation burden (TMB) of patients with LUAD from The Cancer Genome Atlas (TCGA) database. In addition, we constructed a prognostic signature based on six UbRGPs and evaluated its performance in an internal (TCGA testing set) and an external validation set (GSE13213). The prognostic signature revealed that risk scores were negatively correlated with the overall survival, immunocyte infiltration, and expression of immune checkpoint inhibitor-related genes and positively correlated with the TMB. Patients in the high-risk group showed higher sensitivity to partially targeted and chemotherapeutic drugs than those in the low-risk group. This study contributes to the understanding of the characteristics of UbRGPs in LUAD and provides guidance for effective immuno-, chemo-, and targeted therapy.
肺腺癌(LUAD)是全球常见的肺癌病理类型,迫切需要新的生物标志物来指导患者进行更有效的个体化治疗。泛素相关基因(UbRGs)部分参与肺癌的发生和发展。在本研究中,我们利用肿瘤组织中的泛素相关基因对(UbRGPs),从癌症基因组图谱(TCGA)数据库中探究UbRGs在LUAD患者总生存、免疫细胞浸润和肿瘤突变负担(TMB)方面的功能。此外,我们基于六个UbRGPs构建了一个预后特征,并在内部(TCGA测试集)和外部验证集(GSE13213)中评估了其性能。该预后特征显示,风险评分与总生存、免疫细胞浸润以及免疫检查点抑制剂相关基因的表达呈负相关,与TMB呈正相关。高风险组患者对部分靶向药物和化疗药物的敏感性高于低风险组患者。本研究有助于了解LUAD中UbRGPs的特征,并为有效的免疫治疗、化疗和靶向治疗提供指导。